|
It’s not like I could ignore it—that email last week from The New York Times. Not on a story about compounding. And not as the industry trade association.
I had to respond. That, or read “The Alliance for Pharmacy Compounding declined to comment” in the finished article.
Maybe you saw the piece, published this past Monday, about at-home use of ketamine. Maybe you read about how “so-called compounding pharmacies” occupy “a murky regulatory space” and how, with the loosening of restrictions during the Public Health Emergency, compounding “found a market for tablet and lozenge versions of ketamine.”
One might think you’d been out panning for controlled-substance compounding gold and—lo and behold!—ketamine was what landed in your bucket.
I’m both quoted and paraphrased in the piece – and not in a way that illuminates compounding’s essential role in healthcare or the un-murky regulatory framework in which you operate or our concerns with FDA’s arguments about interstate shipments (which the reporter raises).
No. In fact, I had a lot more to say about those things, contextualizing those issues in my responses to the reporter’s questions.
Why am I telling you this? Because you shouldn’t take at face value everything you read in the newspaper. Because I want you to know what we did say to that reporter. (You can read my written responses here.) And because people are watching your profession—which is just another reason to do what you always do with the highest integrity, care, and compliance.
Scott Brunner, CAE, is APC’s chief executive officer. Contact him at scott@a4pc.org.
| 
